1
|
Maeda SS and Lazaretti-Castro M: An
overview on the treatment of postmenopausal osteoporosis. Arq Bras
Endocrinol Metabol. 58:162–171. 2014. View Article : Google Scholar : PubMed/NCBI
|
2
|
Silverman SL: Paget disease of bone:
therapeutic options. J Clin Rheumatol. 14:299–305. 2008. View Article : Google Scholar : PubMed/NCBI
|
3
|
Sugawara S, Shibazaki M, Takada H, Kosugi
H and Endo Y: Contrasting effects of an aminobisphosphonate, a
potent inhibitor of bone resorption, on lipopolysaccharide-induced
production of interleukin-1 and tumour necrosis factor alpha in
mice. Br J Pharmacol. 125:735–740. 1998. View Article : Google Scholar : PubMed/NCBI
|
4
|
Amagase K, Inaba A, Senta T, et al:
Gastric ulcerogenic and healing impairment effects of risedronate,
a nitrogen-containing bisphosphonate in rats. Comparison with
alendronate and minodronate. J Physiol Pharmacol. 62:609–618.
2011.
|
5
|
Richards PJ, Amos N, Williams AS and
Williams BD: Pro-inflammatory effects of the aminobisphosphonate
ibandronate in vitro and in vivo. Rheumatology (Oxford).
38:984–991. 1999. View Article : Google Scholar
|
6
|
Diel IJ, Bergner R and Grötz KA: Adverse
effects of bisphosphonates: current issues. J Support Oncol.
5:475–482. 2007.
|
7
|
Watts NB and Diab DL: Long-term use of
bisphosphonates in osteoporosis. J Clin Endocrinol Metab.
95:1555–1565. 2010. View Article : Google Scholar : PubMed/NCBI
|
8
|
Fleisch H: Bisphosphonates: mechanisms of
action. Endocr Rev. 19:80–100. 1998. View Article : Google Scholar : PubMed/NCBI
|
9
|
Frenkel J, Rijkers GT, Mandey SH, et al:
Lack of isoprenoid products raises ex vivo interleukin-1beta
secretion in hyperimmunoglobulinemia D and periodic fever syndrome.
Arthritis Rheum. 46:2794–2803. 2002. View Article : Google Scholar : PubMed/NCBI
|
10
|
Goldstein JL and Brown MS: Regulation of
the mevalonate pathway. Nature. 343:425–430. 1990. View Article : Google Scholar : PubMed/NCBI
|
11
|
Drenth JP, van Deuren M, van der
Ven-Jongekrijg J, Schalkwijk CG and van der Meer JW: Cytokine
activation during attacks of the hyperimmunoglobulinemia D and
periodic fever syndrome. Blood. 85:3586–3593. 1995.PubMed/NCBI
|
12
|
Haas D and Hoffmann GF: Mevalonate kinase
deficiencies: from mevalonic aciduria to hyperimmunoglobulinemia D
syndrome. Orphanet J Rare Dis. 1:132006. View Article : Google Scholar : PubMed/NCBI
|
13
|
Mandey SH, Kuijk LM, Frenkel J and
Waterham HR: A role for geranylgeranylation in interleukin-1beta
secretion. Arthritis Rheum. 54:3690–3695. 2006. View Article : Google Scholar : PubMed/NCBI
|
14
|
Marcuzzi A, Piscianz E, Kleiner G, et al:
Clinical genetic testing of periodic Fever syndromes. Biomed Res
Int. 2013:5013052013. View Article : Google Scholar : PubMed/NCBI
|
15
|
Tricarico PM, Marcuzzi A, Piscianz E, et
al: Mevalonate kinase deficiency and neuroinflammation: balance
between apoptosis and pyroptosis. Int J Mol Sci. 14:23274–23288.
2013. View Article : Google Scholar : PubMed/NCBI
|
16
|
Cantarini L, Vitale A, Magnotti F, et al:
Weekly oral alendronate in mevalonate kinase deficiency. Orphanet J
Rare Dis. 8:1962013. View Article : Google Scholar : PubMed/NCBI
|
17
|
Attout H, Guez S, Ranaivo I, Jameerbaccus
N and Series C: A patient with hyper-IgD syndrome responding to
simvastatin treatment. Eur J Intern Med. 19:e82–e83. 2008.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Simon A, Drewe E, van der Meer JW, et al:
Simvastatin treatment for inflammatory attacks of the
hyperimmunoglobulinemia D and periodic fever syndrome. Clin
Pharmacol Ther. 75:476–483. 2004. View Article : Google Scholar : PubMed/NCBI
|
19
|
van der Hilst JC, Bodar EJ, Barron KS, et
al: Long-term follow-up, clinical features and quality of life in a
series of 103 patients with hyperimmunoglobulinemia D syndrome.
Medicine (Baltimore). 87:301–310. 2008. View Article : Google Scholar
|
20
|
Hoffmann GF, Charpentier C, Mayatepek E,
et al: Clinical and biochemical phenotype in 11 patients with
mevalonic aciduria. Pediatrics. 91:915–921. 1993.PubMed/NCBI
|